OS Therapies Inc. Unveils Corporate Presentation Highlighting Listeria Platform and Cancer Immunotherapy Advances
Reuters
Sep 11, 2025
<a href="https://laohu8.com/S/OSTX">OS Therapies</a> Inc. Unveils Corporate Presentation Highlighting Listeria Platform and Cancer Immunotherapy Advances
OS Therapies Inc. has released a corporate presentation detailing their advancements and investment highlights. Over $300 million has been invested in their listeria platform, with a focus on the OST-HER2 program targeting osteosarcoma and other solid tumor cancers. The total addressable market for these assets and applications is estimated at $258 billion. The presentation also outlines their OST-tADC platform, featuring a unique patented silicone linker aimed at improving safety and efficacy. The company's clinical-stage pipeline includes programs in osteosarcoma, HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer, with positive Phase 2b data in some areas. OS Therapies is targeting accelerated approval for certain programs in late 2025. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.